IPSEY News and Press, Ipsen SA ADR

2024-07-05 13:41:36 ET More onHutchmed, Ipsen S.A., etc. Ipsen expands collaboration agreement with Exelixis Ipsen gains accelerated approval for elafibranor for rare liver disease Seeking Alpha’s Quant Rating on Hutchison China MediTech Historica...

2024-07-02 03:34:12 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen gains accelerated approval for elafibranor for rare liver disease Ipsen and Marengo Therapeutics announce second strategic partnership ...

2024-06-10 17:33:20 ET More on Ipsen Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen and Marengo Therapeutics announce second strategic partnership Ipsen S.A. reports Q1 results; reaffirms full-year guidance Historical ...

2024-06-07 08:53:26 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen S.A. reports Q1 results; reaffirms full-year guidance Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases ...

2024-05-29 13:52:41 ET Summary Genfit S.A. has a PDUFA date of June 10, 2024, by which time the FDA will decide upon whether elafibranor should be approved to treat patients with primary biliary cholangitis. European marketing approval of elafibranor for treatment of patients with...

2024-05-02 12:28:33 ET Summary EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue are at stake. I'm not holding shares through the ...

2024-04-24 02:26:32 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases Ipsen secures exclusive global rights of Sutro Biopharma's STR...

2024-04-22 02:47:42 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC Ipsen gets FDA approval for pancreatic cancer drug regimen Hist...

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...

2024-04-05 18:31:56 ET Summary Ipsen S.A. is a pharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of commercial drug products. The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m. Ipsen typica...